Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 19/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31189809 | 1.00 | EZH2 (1.00) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL20111746 | 1.00 | EZH2 (1.00) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL16935365 | 0.96 | EZH2 (0.92) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL16935285 | 0.96 | EZH2 (0.92) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL24072447 | 0.94 | EZH2 (0.90) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL16935191 | 0.94 | EZH2 (0.89) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL16935220 | 0.94 | EZH2 (0.88) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL24071944 | 0.94 | EZH2 (0.88) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL21284965 | 0.93 | EZH2 (0.87) | EZH2EZH1HDAC1HDAC6 | |
| SCHEMBL21284967 | 0.93 | EZH2 (0.87) | EZH2EZH1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025085536-A1 | BIOLOGIC CONJUGATES THAT INHIBIT PRODUCTION OF INFLAMMATORY CELLS AND METHODS OF USE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2025049966-A9 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025049966-A2 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | WASIK MARIUSZ A (US) | 2025-03-06 | — | — | WO | claimed |
| CN-119326889-A | PHGDH inhibitor and application thereof in treatment of disseminated tumor cells | 复旦大学附属中山医院 | 2025-01-21 | — | — | CN | claimed |
| US-20240408081-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM (FR) | 2024-12-12 | — | — | US | claimed |
| EP-4423254-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | Memorial Sloan Kettering Cancer Center (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240279600-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-08-22 | — | — | US | claimed |
| EP-4401719-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2024-07-24 | — | — | EP | claimed |
| WO-2023076554-A9 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-07-11 | — | — | WO | claimed |
| CN-117979962-A | Novel synergistic combinations for treating cancer and methods of use thereof | 波尔多大学 | 2024-05-03 | — | — | CN | claimed |
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| CN-117503930-A | Application of PRC2 complex as target in developing medicine for preventing and treating neurodegenerative diseases or central nerve injury diseases | 北京干细胞与再生医学研究院 | 2024-02-06 | — | — | CN | claimed |
| WO-2023249714-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR ACTIVATING DOUBLE STRANDED RNA RESPONSE IN CANCER PATIENTS VIA DNMT1 TARGETED THERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-12-28 | — | — | WO | claimed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | claimed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | claimed |
| WO-2023041674-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | Universite de Bordeaux (FR) | 2023-03-23 | — | — | WO | claimed |
| EP-4151208-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USES THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2023-03-22 | — | — | EP | claimed |
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | disclosed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12599662-B2 | Methods and compositions for treating cancers | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2026-04-14 | — | — | US | disclosed |
| US-12403110-B2 | Methods and compositions for treating cancers | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2025-09-02 | — | — | US | disclosed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025085536-A1 | BIOLOGIC CONJUGATES THAT INHIBIT PRODUCTION OF INFLAMMATORY CELLS AND METHODS OF USE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025049966-A9 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025049966-A2 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | WASIK MARIUSZ A (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119326889-A | PHGDH inhibitor and application thereof in treatment of disseminated tumor cells | 复旦大学附属中山医院 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-20240408081-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM (FR) | 2024-12-12 | — | — | US | disclosed |
| US-20240390379-A1 | EZH2 Inhibition in Pancreatic Cancer | UNIV MASSACHUSETTS (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4423254-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | Memorial Sloan Kettering Cancer Center (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279600-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4401719-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023076554-A9 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-117979962-A | Novel synergistic combinations for treating cancer and methods of use thereof | 波尔多大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-117503930-A | Application of PRC2 complex as target in developing medicine for preventing and treating neurodegenerative diseases or central nerve injury diseases | 北京干细胞与再生医学研究院 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023249714-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR ACTIVATING DOUBLE STRANDED RNA RESPONSE IN CANCER PATIENTS VIA DNMT1 TARGETED THERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230338494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | INST NAT SANTE RECH MED (FR) | 2023-10-26 | — | — | US | disclosed |
| US-20230310421-A1 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2023-10-05 | — | — | US | disclosed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-116376812-A | Methods and compositions for treating cancer | 国家医疗保健研究所 | 2023-07-04 | — | — | CN | disclosed |
| US-11679148-B2 | Methods and compositions for treating cancers | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2023-06-20 | — | — | US | disclosed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023055885-A2 | EZH2 INHIBITION IN PANCREATIC CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023041674-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | Universite de Bordeaux (FR) | 2023-03-23 | — | — | WO | disclosed |
| EP-4151208-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USES THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2023-03-22 | — | — | EP | disclosed |
| EP-4135679-A1 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Istituto Europeo di Oncologia S.r.l. (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-20220411879-A1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EFFICACY OF EGFR-TARGETED ANTI-CANCER AGENTS | THE GENERAL HOSPITAL CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220370582-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | UNIVERSITÉ PARIS CITE (FR) | 2022-11-24 | — | — | US | disclosed |
| US-11458194-B2 | Methods and compositions for treating cancers | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-10-04 | — | — | US | disclosed |
| US-20220298222-A1 | COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS | JUNO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4058604-A1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4017527-A1 | COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS | Juno Therapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-111393509-B | Target specific polypeptide and application thereof | 国家纳米科学中心 | 2022-03-29 | — | — | CN | disclosed |
| WO-2022058405-A2 | HISTONE DEACETYLASE INHIBITORS AND USES THEREOF | IFOM - ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-03-24 | — | — | WO | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | EZH2 14/4885EZH1 28/4885HDAC1 91/4885 |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885HDAC1 73/4885 |
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885HDAC1 136/4885 |
| US-20230338494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | CD74, CD47, TP53 | EZH2 432/4885EZH1 1200/4885HDAC1 712/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885HDAC1 73/4885 |
| US-11679148-B2 | Methods and compositions for treating cancers | CD74, CD47, TP53 | EZH2 432/4885EZH1 1200/4885HDAC1 712/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | EZH2 90/4885EZH1 41/4885HDAC1 9/4885 |
| US-12403110-B2 | Methods and compositions for treating cancers | CD74, CD47, TP53 | EZH2 432/4885EZH1 1200/4885HDAC1 712/4885 |
| US-20230310421-A1 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | IRF3, EIF2AK2, MAVS | EZH2 37/4885EZH1 49/4885HDAC1 28/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885HDAC1 73/4885 |
| US-20220298222-A1 | COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS | EZH2, IKZF2, ICOS | EZH2 1/4885EZH1 7/4885HDAC1 158/4885 |
| US-11458194-B2 | Methods and compositions for treating cancers | HLA-C, HLA-A, BRCA1 | EZH2 37/4885EZH1 301/4885HDAC1 16/4885 |
| US-12599662-B2 | Methods and compositions for treating cancers | TLR3, TLR7, TLR9 | EZH2 58/4885EZH1 230/4885HDAC1 51/4885 |
| US-20220370582-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | HLA-C, HLA-A, BRCA1 | EZH2 37/4885EZH1 301/4885HDAC1 16/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | EZH2 318/4885EZH1 509/4885HDAC1 3440/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | EZH2 4285/4885EZH1 3481/4885HDAC1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.